The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Rasulov A.O.
Department of colorectal cancer
Jumabaev Kh.E.
Department of colorectal cancer
Kozlov N.A.
Department of Proctology and Department of Pathomorphology of N.N. Blokhin Russian Research Oncology Center, Moscow, Russia
Suraeva Yu.E.
Blokhin National Medical Cancer Research Center of Healthcare Ministry of Russia, Moscow, Russia
Mamedli Z.Z.
Department of colorectal cancer
Kulushev V.M.
Department of colorectal cancer
Gordeev S.S.
Blokhin National Medical Cancer Research Center of Healthcare Ministry of Russia, Moscow, Russia
Kuzmichev D.V.
Department of colorectal cancer
Polynovsky A.V.
Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow
Transanal mesorectumectomy for rectal cancer — is it optimal surgery for «difficult» patients?
Journal: Pirogov Russian Journal of Surgery. 2018;(6): 4‑21
Views: 1079
Downloaded: 21
To cite this article:
Rasulov AO, Jumabaev KhE, Kozlov NA, et al. . Transanal mesorectumectomy for rectal cancer — is it optimal surgery for «difficult» patients?. Pirogov Russian Journal of Surgery.
2018;(6):4‑21. (In Russ.)
https://doi.org/10.17116/hirurgia201864-21
Aim. To compare short-term outcomes after transanal total mesorectumectomy (Ta-TME) and laparoscopic (Lap-TME) procedure in «difficult» patients. Material and methods. Prospective nonrandomized trial included patients with confirmed middle-/low rectum adenocarcinoma T1-4aN0-2M0 for the period November 2013 — September 2016. We identified 20 out of 55 in TA-TME and 14 out of 54 patients in Lap-TME group as those of «difficult» subgroup: male, BMI ≥25 кг/м2, previous chemoradiotherapy (CRT). Results. Time of surgery, blood loss, conversions rate, postoperative morbidity and length of hospital-stay were similar in both groups. Hardware anastomoses were more frequent in TA-TME compared with LAP-TME group (78.9% vs. 50%, p=0.086). Specimen quality was more favorable in TA-TME group: Grade I 10% in Ta-TME group vs. 28.6% in Lap-TME group; «positive» CRM 5% vs. 14.3%, р=0.365. Within-group analysis did not reveal any differences between «difficult» and «typical» patients by surgical and pathomorphological characteristics in TA-TME group in contrast to Lap-TME group. Median of follow-up was 24.6 (IR 10.6—40.2) and 23.8 (IR 12.1—39.9) months for TA-TME and Lap-TME groups, respectively. Local recurrence occurred in 1 (1.8%) «difficult» patient after Ta-TME. Distant metastases were observed in 1 (1.8%) patient of Ta-TME and 2 (3.7%) patients of Lap-TME group. Actuarial 3-years reccurence-free survival was 95.7% for Ta-TME and 93.9% for Lap-TME group, respectively (p=0.923). Conclusion. TA-TME is advisable for “difficult” patients. Further multicenter randomized trials are necessary to specify the effectiveness of TA-TME in these patients.
Authors:
Rasulov A.O.
Department of colorectal cancer
Jumabaev Kh.E.
Department of colorectal cancer
Kozlov N.A.
Department of Proctology and Department of Pathomorphology of N.N. Blokhin Russian Research Oncology Center, Moscow, Russia
Suraeva Yu.E.
Blokhin National Medical Cancer Research Center of Healthcare Ministry of Russia, Moscow, Russia
Mamedli Z.Z.
Department of colorectal cancer
Kulushev V.M.
Department of colorectal cancer
Gordeev S.S.
Blokhin National Medical Cancer Research Center of Healthcare Ministry of Russia, Moscow, Russia
Kuzmichev D.V.
Department of colorectal cancer
Polynovsky A.V.
Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.